Zion Labs T-5 (ECA)

Description Zion Labs T-5 (ECA Stack) Brand: Zion Labs Category: Thermogenic · High-stim ECA (Ephedrine Caffeine Aspirin) Content: 90 capsules Per Capsule (Label): Ephedrine 30 mg · Caffeine 250 mg · Aspirin 150 mg Manufactured in: Cyprus Price: €22 Research Notice: For laboratory and analytical use only. Not for human or veterinary consumption. ???? Product Overview T-5 by Zion Labs is a classical ECA stack combining ephedrine, caffeine, and aspirin into a single high-stimulus capsule aimed at research on: thermogenesis and metabolic stimulation adrenergic signaling and norepinephrine-driven pathways energy, focus, and pre-exercise arousal body-mass and calorie-restriction models stimulant synergy (ephedrine caffeine) ECA protocols are extensively referenced in older metabolic and obesity studies, making T-5 a structured stimulant model for comparative research. ✅ Key Research Highlights Ephedrine (30 mg): Indirect sympathomimetic that increases norepinephrine release and stimulates β-adrenergic receptors → promotes lipolysis, thermogenesis, and increased energy expenditure. Studies consistently show enhanced thermogenesis when paired with caffeine. Caffeine (250 mg): Adenosine A1/A2A antagonist → heightened CNS arousal, reduced perceived effort, improved alertness, and potential metabolic increases. Commonly researched in performance and weight-management contexts. Aspirin (150 mg): Included historically in ECA protocols; proposed to attenuate prostaglandin-mediated feedback. Evidence suggests limited enhancement beyond EC alone but remains part of traditional triads. ???? Mechanism of Action (Simplified) Ephedrine: Increases synaptic NE → β-adrenergic activation → lipolysis thermogenic output. Caffeine: Blocks adenosine receptors → boosts alertness, metabolic activity, and enhances ephedrine response. Aspirin: Historically added to prolong thermogenic signaling (evidence variable). ???? Technical Specification Table Field Data Per-Capsule Actives Ephedrine 30 mg · Caffeine 250 mg · Aspirin 150 mg Pharmacology Ephedrine: β-adrenergic stimulant Caffeine: adenosine A1/A2A antagonist Aspirin: COX inhibitor (ECA protocol component) Evidence Snapshot (ECA) Clinical studies show increased thermogenesis and modest weight reduction vs placebo; strong regulatory restrictions due to cardiovascular/CNS risks. Doping Status Ephedrine prohibited in-competition above 10 µg/mL urine. Caffeine not prohibited, but monitored in some sports. Regulatory Note Ephedrine-alkaloid supplements banned in U.S. (FDA); restricted across many jurisdictions. Origin Cyprus ???? Research Background ECA literature: Studies indicate increased metabolic rate and short-term body-mass reduction via β-adrenergic stimulation and caffeine synergy. Caffeine potentiation: Caffeine enhances ephedrine’s thermogenic effect in multiple controlled papers. Safety drives regulation: Cardiovascular and CNS risks prompted global regulatory tightening. ⚠️ Potential Side Effects (Class-Based Literature) Elevated blood pressure, tachycardia, palpitations Insomnia, anxiety, tremors, agitation Headache, nausea, GI discomfort Rare severe events: arrhythmia, stroke, myocardial infarction Risk increases when combined with other stimulants or MAO inhibitors ???? Compliance & Doping Status Sport: Ephedrine is prohibited in-competition above 10 µg/mL urine under WADA rules. Athletes should avoid use and consult federation guidelines. Regulation: Ephedrine-containing dietary supplements are illegal in the U.S. and restricted in many jurisdictions. Importation or sale may be blocked by authorities. Research-only: Not a supplement or medication. No human consumption implied. Supplied for analytical, forensic, and laboratory work only. ???? Important Notice For research use only. Not a dietary supplement, not a medicine, and not for performance enhancement. Users must follow local laws, laboratory safety policies, and anti-doping rules.